/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Flot.bio x Philip Hemme
  2. MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62
MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62

MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62

Flot.bio x Philip Hemme · Sep 28, 2026

MedinCell CEO Christophe Douat on disrupting psychiatric care with long-acting injectables, achieving a $1B+ valuation, and their 20-year journey.

MedinCell CEO Argues Drug Delivery Is as Critical as Drug Development

In the pharma industry, prestige lies in drug development. However, the delivery mechanism is equally crucial for a drug's success, affecting compliance, efficacy, and ultimately, commercial viability. Companies often fail to integrate delivery strategy early enough, but this is starting to shift.

MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62 thumbnail

MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62

Flot.bio x Philip Hemme·2 months ago

Eli Lilly's Past Technical Failure Creates a Long-Term Moat for MedinCell's Olanzapine

A major competitor, Eli Lilly, previously failed to create a long-acting injectable for the drug olanzapine due to technical issues. This historical failure has deterred other companies, leaving MedinCell with a significant competitive advantage and no direct competition for the foreseeable future.

MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62 thumbnail

MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62

Flot.bio x Philip Hemme·2 months ago

Running a Rural Canadian Fishing Lodge Provided Invaluable CEO Training

MedinCell's CEO credits his experience running a remote fishing lodge with teaching him essential business skills. The role required managing logistics, HR, finance, and operations for 35 employees and 700 flights in five months, providing a real-world MBA in entrepreneurship.

MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62 thumbnail

MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62

Flot.bio x Philip Hemme·2 months ago

MedinCell Grew by Operating as a Commercial Entity, Avoiding VC Money

Unlike typical biotechs, MedinCell developed without venture capital or angel investment. They focused on operating as a commercial entity from the start, “tightening their belt to the tenth degree.” This unconventional path forced extreme capital efficiency but may have slowed talent acquisition.

MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62 thumbnail

MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62

Flot.bio x Philip Hemme·2 months ago

MedinCell Leveraged Montpellier's Academic Ecosystem to Become a Global Leader

MedinCell's location in Montpellier, France, was a strategic choice, not an accident. The city is a major research hub with a deep history in medicine and pharmacy, home to the "Pope of PLA polymers." This ecosystem provided the foundational science and talent for the company's success.

MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62 thumbnail

MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62

Flot.bio x Philip Hemme·2 months ago

Long-Acting Drugs Expand the Patient Market, Not Just Steal Share

Rather than just taking market share from existing treatments, successful long-acting injectables expand the total addressable market. Analysts predict they will grow the treated patient population in schizophrenia from 13% to 20% by 2030 by improving compliance and outcomes.

MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62 thumbnail

MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62

Flot.bio x Philip Hemme·2 months ago

French-Listed MedinCell Attracted US Funds by Systematically Targeting Them for 3 Years

MedinCell, listed only on Euronext in France, successfully attracted significant US investment by dedicating three years to systematic outreach. This rare achievement involved direct engagement, leading to US funds buying shares directly on the European exchange and attracting US bank analyst coverage.

MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62 thumbnail

MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62

Flot.bio x Philip Hemme·2 months ago